Breaking News

Emergence Therapeutics Closes €87 Million Series A Financing Round

Plans to advance its Nectin-4 antibody drug conjugate.

Author Image

By: Charlie Sternberg

Associate Editor

Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, has closed an €87 million ($97.9 million) series A financing round.   The round was led by Pontifax Venture Capital and includes RA Capital Management, OrbiMed Advisors, Surveyor Capital (a Citadel company) and Hadean Ventures as new investors as well as existing investors Kurma Partners, NRW.BANK, High-Tech Gründerfonds, Gründerfonds Ruhr and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters